Page 539«..1020..538539540541..550560..»

Scientists Discover How To Halt and Control Cellular Death Process Previously Thought To Be Irreversible – SciTechDaily

Posted: January 20, 2022 at 2:03 am

A composite image of a cell throughout pyroptosis. Credit: Gary Mo

A study published by researchers at the University of Illinois Chicago describes a new method for analyzing pyroptosis the process of cell death that is usually caused by infections and results in excess inflammation in the body and shows that process, long thought to be irreversible once initiated, can in fact be halted and controlled.

The discovery, which is reported in Nature Communications, means that scientists have a new way to study diseases that are related to malfunctioning cell death processes, like some cancers, and infections that can be complicated by out-of-control inflammation caused by the process. These infections include sepsis, for example, and acute respiratory distress syndrome, which is among the major complications of COVID-19 illness.

Pyroptosis is a series of biochemical reactions that uses gasdermin, a protein, to open large pores in the cell membrane and destabilize the cell. To understand more about this process, the UIC researchers designed an optogenetic gasdermin by genetically engineering the protein to respond to light.

The cell death process plays an important role in the body, in both healthy states and unhealthy ones, but studying pyroptosis which is a major type of cell death has been challenging, said Gary Mo, UIC assistant professor in the department of pharmacology and regenerative medicine and the department of biomedical engineering at the College of Medicine.

Mo said that methods to examine the pyroptosis mechanisms at play in live cells are difficult to control because they are initiated by unpredictable pathogens, which in turn have disparate effects in different cells and people.

Our optogenetic gasdermin allowed us to skip over the unpredictable pathogen behavior and the variable cellular response because it mimics at the molecular level what happens in the cell once pyroptosis is initiated, Mo said.

The researchers applied this tool and used florescent imaging technology to precisely activate gasdermin in cell experiments and observe the pores under various circumstances. They discovered that certain conditions, like specific concentrations of calcium ions, for example, triggered the pores to close within only tens of seconds.

This automatic response to external circumstances provides evidence that pyroptosis dynamically self-regulates.

This showed us that this form of cell death is not a one-way ticket. The process is actually programmed with a cancel button, an off-switch, Mo said. Understanding how to control this process unlocks new avenues for drug discovery, and now we can find drugs that work for both sides it allows us to think about tuning, either boosting or limiting, this type of cell death in diseases, where we could previously only remove this important process.

Reference: Gasdermin D pores are dynamically regulated by local phosphoinositide circuitry by Ana Beatriz Santa Cruz Garcia, Kevin P. Schnur, Asrar B. Malik and Gary C. H. Mo, 10 January 2022, Nature Communications.DOI: 10.1038/s41467-021-27692-9

Co-authors of the Nature Communications paper, Gasdermin D Pores Are Dynamically Regulated by Local Phosphoinositide Circuitry, areAna Santa Cruz Garcia, Kevin Schnur and Asrar Malik, all of UIC.

The research was funded with grants from the National Institutes of Health (P01HL060678, R01HL090152, R01HL152515, T32HL007820, P01HL151327).

Follow this link:
Scientists Discover How To Halt and Control Cellular Death Process Previously Thought To Be Irreversible - SciTechDaily

Posted in Cell Medicine | Comments Off on Scientists Discover How To Halt and Control Cellular Death Process Previously Thought To Be Irreversible – SciTechDaily

Optimized Treatment Starts With Molecular Testing in NSCLC – OncLive

Posted: January 20, 2022 at 2:03 am

Although survival data from the large, phase 3 ADAURA (NCT02511106)and CROWN (NCT03052608) trials are still anticipated in advanced nonsmall cell lung cancer (NSCLC), molecular testing should not be withheld from patients with nonsmall cell lung cancer (NSCLC) in the interim, according to Konstantinos Arnaoutakis, MD, who added that the primary results from both studies warrant discussion with patients.

Molecular testing is important, and the use of liquid biopsies is also very important. The earlier you have that information, the better and more tailored therapy you can provide to patients, said Arnaoutakis in an interview with OncLive following an Institutional Perspectives in Cancer (IPC) webinar on lung cancer.

In the interview, Arnaoutakis, a hematologist, oncologist, and associate professor in the Department of Internal Medicine and Division of Hematology and Oncology at the Winthrop P. Rockefeller Cancer Institute and the University of Arkansas for Medical Sciences, discussed new strategies in the management of ALK-positive NSCLC, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.

Arnaoutakis: The IPC meeting was designed to educate health care professionals on the clinical benefits associated with the science driving lung cancer management. I hope that attendees not only improved their knowledge of new treatment approaches, but also left the event with confidence of how to apply state of the art treatment strategies to care for their patients. We assembled academic physicians, which focused on the most relevant lung cancer topics like EGFR-directed treatments, immunotherapy, ALK-positive disease, and new biomarkers to improve patient care.

Molecular testing in the management of lung cancer is very important, and even though testing is important, treatment based on testing doesnt happen as often as we think for a variety of reasons. [Some of the reasons may be] that tissue is not available, there are delays getting results back, or even the type of testing. Oftentimes, repeat biopsies and circulating tumor DNA testing through a liquid biopsy platform could address these issues. Also, there is a growing number of FDA-approved treatments. Were in this fortunate position that we have at least 9 FDA-approved biomarkers, including tumor mutational burden and emerging biomarkers like HER2 mutations and MET amplification. However, the growing number of treatments is causing some issues. Theres a learning curve for oncologists to learn how to use these drugs, trying to decide which drug to use and how to manage adverse effects [AEs]. Those are important topics and issues that we need to address and learn about.

Some molecular abnormalities are uncommon, so funding can be an issue. Good trial designs are also important. Many of these new drugs are approved through phase 2 studies because its very difficult to have phase 3 randomized studies for these relatively uncommon, molecular abnormalities. Collaboration among different institutions is paramount to gather a good number of participants. A recent example is the NRG1 fusions, which are oncogenic drivers across multiple tumor types, including lung cancer, but these are difficult to study because of their rarity.

There was a recent Journal of Clinical Oncology article; the first author was Dr Alexander Drilon, and Dr Stephen Liu was the last author. This was a global international registry that was established to characterize NRG1 fusionpositive lung cancer. Some of these [series] are examples of international multicenter collaborations that are very important. Another issue is the mechanism of resistance [associated with these agents], which is important since resistance, in some ways is unavoidable, at least for now. Another example is the NTRK fusions, for which we already have 2 agents that try to address that issue. These are drugs that are targeting the NTRK mutations that are causing the resistance.

Dr Dimou discussed the results of the CROWN study where lorlatinib [Lorbrena] was tested. Lorlatinib is now approved by the FDA for use in patients with newly diagnosed ALK-positive NSCLC, joining ceritinib [Zykadia], alectinib [Alecensa], brigatinib [Alunbrig], and crizotinib [Xalkori] as first-line therapy options. Its a very crowded field, and in the absence of head-to-head data with alectinib, we are left to decide how to use the very promising CROWN data in practice.

Many people propose to use lorlatinib as the preferred frontline TKI since it had probably the best-in-class overall progression-free survival hazard ratio and CNS [central nervous system] efficacy. Patients taking lorlatinib had markedly improved time to CNS progression, and the 12-month cumulative incidence of CNS progression was just 3% compared with 33% with crizotinib and about 9% or 10% with alectinib in the ALEX study [NCT02075840].

For now, some people are favoring using lorlatinib as a frontline option. I and some others continue to favor alectinib or brigatinib as we wait for [additional] results from the CROWN study. Its something that must be thought about carefully. There are some AEs that must be factored in. Of course, the presence or absence of CNS metastases should be a critical factor since lorlatinib seems to have very good CNS penetration.

The use of adjuvant osimertinib [Tagrisso] demonstrated a statistically significant and clinically meaningful benefit for patients with stage IB, II, and IIIA EGFR-mutant lung cancer after complete tumor resection in the phase 3 ADAURA trial [NCT02511106]. The trial results were very impressive. They found that adjuvant therapy with osimertinib was associated with almost an 80% reduction in the risk of disease recurrence or death in patients with stage IB to IIIA EGFR-mutant lung cancer. The staging that was used in the trial was the 7th edition staging even though we currently use the 8th edition staging.

In the study, osimertinib was compared with placebo for a treatment duration of up to 3 years or until disease recurrence. The primary end point in this study was disease-free survival [DFS], and the key secondary end point was overall survival. The study was unblinded early under the recommendation of the independent data monitoring committee because of efficacy, and at the time of the unblinding, the randomized patients had been followed for at least 1 year, and the DFS curve separated early such that there was almost an 80% reduced risk of disease recurrence for the osimertinib arm, which is impressive. That benefit was seen across all stages, particularly stage II and III.

Its very exciting that we have an adjuvant option for patients with EGFR-mutant disease, which, in the United States is about 15% of all patients with lung cancer and in Asia is about 30%. Adjuvant osimertinib is another option for a good chunk of patients with lung cancer. There is of course criticism about the fact that we dont know yet about the survival benefit only the DFS, so that adds another point of conversation with patients, but a lot of oncologists are already discussing [adjuvant osimertinib] and testing patients with early-stage lung cancer for EGFR, because if you dont test for it, you wont know if they have an EGFR mutation.

We have a lot of new studies on frontline immunotherapy. CheckMate 227 [NCT02477826] and CheckMate 9LA [NCT03215706] are important studies. CheckMate 227 evaluated the combination of ipilimumab [Yervoy] and nivolumab [Opdivo] as frontline therapy. CheckMate 9LA employed 2 cycles of chemotherapy along with ipilimumab and nivolumab. These studies are important because they are adding to the information that we have from the KEYNOTE-189 [NCT02578680] and KEYNOTE-407 [NCT02775435] trials for patients with nonsquamous and squamous cell carcinoma.

We are in a fortunate position to be able to decide between different treatments; all these regimens are good, viable therapies. We must use our judgement to decide which regimen to use, considering how the patients can tolerate chemotherapy.

For example, if a patient is unable to tolerate cytotoxic chemotherapy, the CheckMate 227 regimen is a very reasonable approach for patients who have a PD-L1 expression of more than 1%. Also, some patients may have more aggressive disease where we want to incorporate cytotoxic chemotherapy up front. Of course, a discussion with the patient [that considers their] preferences is important because some patients are not interested in receiving chemotherapy, and thats something that has to be factored in. It can be confusing for many thoracic oncologists about what the optimal regimen is in the front-line setting.

More here:
Optimized Treatment Starts With Molecular Testing in NSCLC - OncLive

Posted in Cell Medicine | Comments Off on Optimized Treatment Starts With Molecular Testing in NSCLC – OncLive

Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology – BioSpace

Posted: January 20, 2022 at 2:02 am

PHILADELPHIA--(BUSINESS WIRE)-- Ceptur Therapeutics, Inc. (Ceptur), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75M Series A financing. The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors along with existing Seed investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners.

We are extremely grateful for the support of our new and existing investors, said Ceptur Therapeutics co-founder, President and CEO P. Peter Ghoroghchian, MD, PhD. In 2021, we in-licensed and internally expanded our foundational IP portfolio on U1 Adaptor technology; we further recruited a world-class scientific advisory board, comprising academic and industry leaders in oligonucleotide therapeutics. Moving forward, Ceptur will use the proceeds of this financing round to advance our broad discovery pipeline of differentiated genetic medicines.

U1 Adaptors are bivalent oligonucleotides that engage sequence-specific mRNA and the U1 small nuclear ribonuclear protein (U1 snRNP), which is a ubiquitous intracellular machine that regulates transcription and splicing. U1 Adaptor therapeutics control gene expression at the pre-mRNA level within the nucleus, affording advantageous properties for drugging difficult targets.

Therapeutic approaches that target RNA have become an essential treatment modality for patients with genetic diseases and a priority for many biopharma companies; we believe that the U1 Adaptor technology is a differentiated approach to RNA regulation that has multiple potential advantages over current technologies, said Aaron Royston, M.D., M.B.A., Managing Partner at venBio Partners. We are excited to further build out Cepturs team and capabilities, to demonstrate these unique applications, and, ultimately, to advance novel therapeutics for patients with genetic diseases.

Colin Walsh, Ph.D., Partner at Qiming Venture Partners USA, added, RNA-based drugs have already become an essential tool in our therapeutic arsenal; and, we strongly believe that this modality will continue to deliver meaningful new therapies for patients. Cepturs use of synthetic oligonucleotides that engage U1 snRNP offers the ability to co-opt this master regulator of the transcriptome to regulate mRNA in a highly targeted fashion. We are thrilled to support Cepturs next phase of growth as they apply this disruptive approach for novel therapeutic applications.

With this financing, Aaron Royston, M.D., M.B.A., and Colin Walsh, Ph.D., join Cepturs Board of Directors.

Daniel Heller, M.S., M.B.A., General Partner and Chief Investment Officer at Affinity Asset Advisors, continued, In leading the Series Seed round, we identified early the potential of U1 Adaptor technology. Over the past year, we have worked closely with Peter and the Ceptur team and are delighted at the progress that has been made towards establishing the platform. In this financing round, we have significantly expanded upon our initial commitment and are inspired to partner with our new investor syndicate to advance U1 Adaptors for unmet patient needs.

To realize the revolutionary potential of the U1 Adaptor technology, several new members join Samuel Gunderson, Ph.D., co-founder of Ceptur, Professor of Molecular Biology at Rutgers University, and a leading expert on U1 snRNP biology, on Cepturs Scientific Advisory Board:

Thomas Andresen, Ph.D. Dr. Thomas L. Andresen is the CEO of T-Cypher Bio and the former CSO of Torque Therapeutics, now Repertoire Immune Medicines. While at Torque, he led the companys cellular immunotherapy programs from early-stage discovery to CMC scaling and through to clinical development. Dr. Andresen is a serial entrepreneur, having founded several US and EU life-science companies that further include Nanovi A/S and Monta Biosciences. His company creation track record spans early discovery to commercial and maps across multiple immunotherapy approaches for oncology. Dr. Andresen sits on several boards/advisory boards, including for Tidal Therapeutics (acquired by Sanofi), Monta Biosciences, and Nanovi; in academia, hes further founded the Institute of Health Technology at the Technical University of Denmark, where he maintains a professorial position. Dr. Andresen has co-authored over >200 research articles, has been listed as an inventor on >45 patent applications, and has received multiple research prizes, including the Elite Research Price from the Danish Ministry of Science.

Dennis Benjamin, Ph.D. Dr. Dennis Benjamin is the former SVP of Research at Seagen where he was a key developer of the companys ADC technology and clinical pipeline. Prior, he worked at Praecis Pharmaceuticals and Genetics Institute, advancing DNA encoded libraries and working in protein and small molecule discovery. Over his career, he has led teams that have discovered 25 biologics and small molecules that entered clinical trials and has contributed to 4 drug approvals. He is currently an advisor and SAB member at several start-up biotechnology companies.

Steven Dowdy, Ph.D. Dr. Steven F. Dowdy is a Professor of Cellular & Molecular Medicine at the UCSD School of Medicine and a cancer biologist, specializing in the development and delivery of RNA therapeutics as well as in G1 cell cycle control in cancer. The Dowdy lab is focused on the molecular details of delivery of RNA therapeutics across the endosomal lipid bilayer as well as the synthesis of endosomal escape domains to overcome this rate-limiting and billion year-old delivery challenge; its members were the first to synthesize bioreversible, charge neutralizing phosphotriester backbone RNAi prodrug triggers that increase metabolic stability, that augment pharmacokinetics and that enhance endosomal escape. Dr. Dowdy currently serves on five Science Advisory Boards for biotech companies and is an elected member of the Oligonucleotide Therapeutics Society (OTS) Board of Directors.

Sridhar Ganesan, M.D., Ph.D. Dr. Shridar Ganesan is the Associate Director for Translational Science, Chief of the Section of Molecular Oncology, and the co-Leader of the Clinical Investigations and Precision Therapeutics Program at the Rutgers Cancer Institute of New Jersey; he is also the Omar Boraie Chair in Genomic Science and Professor of Medicine at the Rutgers Robert Wood Johnson Medical School. Dr. Ganesan is a medical oncologist with clinical expertise in triple-negative breast cancer, hereditary breast cancer and rare cancer. His research interests include the characterization of DNA repair abnormalities in cancer with a focus on the BRCA1 tumor suppressor gene, the multi-modal molecular characterizations of different cancers, and the identification of biomarkers of response and resistance in early phase clinical trials. He has authored or co-authored over 120 publications, serves on multiple national and international grant review committees and is an Associate Editor of JCO-Precision Oncology.

Adrian Krainer, Ph.D. Dr. Adrian Krainer is the St Giles Professor at Cold Spring Harbor Laboratory (CSHL) and Deputy Director of Research of the CSHL Cancer Center. A world-renowned biochemist recognized for his basic work on RNA splicing and the development of its mechanism-based therapeutic applications, his seminal work with antisense oligonucleotides in mouse models of spinal muscular atrophy led to the development of nusinersen (Spinraza), which is the first FDA-approved drug for this disease; he is also a co-founder and a member of the Board of Directors at Stoke Therapeutics (NASDAQ: STOK). Dr. Krainer is the recipient of the Life Sciences Breakthrough Prize, the RNA Societys Lifetime Achievement Award, the Reemtsma Foundation International Prize in Translational Neuroscience, the Speiser Award in Pharmaceutical Sciences, and the Ross Prize in Molecular Medicine, amongst others. He previously served as the President of the RNA Society and is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts & Sciences.

Iain Mattaj, Ph.D. Dr. Iain Mattaj is the founding Director of Fondazione Human Technopole in Milan, Italy. Dr. Mattaj has made seminal contributions to the fields of transcription, RNA metabolism, nucleocytoplasmic transport and cell division. His prominent standings in these fields are underlined by his election as the past President of the RNA Society, Fellow of the Royal Society (London), Fellow of the Royal Society of Edinburgh, elected Member of the German Academy of Sciences Leopoldina, Member of Academia Europea, Foreign Honorary Member of the American Academy of Arts and Science, Fellow of the Academy of Medical Sciences (London) and Foreign Associate of the National Academy of Sciences (US). Dr. Mattaj was previously awarded the prestigious Louis-Jeantet Prize for Medicine in 2001. He is further a member of the European Molecular Biology Organization (EMBO) and helped to make The EMBO Journal a highly successful international publication, acting as Executive Editor from 1990 to 2004. Prior to his current appointment, Dr. Mattaj was a member of EMBL Heidelberg, Germany, serving as Group Leader (1985-1990), Coordinator of the Gene Expression Unit (1990-1999), and, subsequently, as the institutes Scientific Director (1999-2005) and Director General (2005-2018).

Henrik Oerum, Ph.D. Dr. Henrik Oerum the co-founder and CSO of Civi BioPharma and has previously founded 3 other oligonucleotide companies. Dr. Oerum has over 25 years of experience in the development and commercialization of oligonucleotide therapeutics, has authored >70 peer reviewed publications, and has been listed as an inventor on numerous patents in the field. In 1993, he founded PNA Diagnostics A/S, where he was also the CSO until 1999. During his tenure at PNA, the company was sold to Boehringer Mannheim (1994) and later to Hoffman-La Roche (1997). In 1996, Dr. Oerum cofounded Exiqon A/S, a nucleic acid diagnostics company that was floated on the Copenhagen Stock Exchange in 2007 (CSE:EXQ). In 2000, he co-founded the LNA-oligotherapeutics company Santaris Pharma A/S, where he served as CSO and VP of Business Development until its acquisition by Roche in 2014. Thereafter, he worked for Roche Pharma as Global Head of RNA therapeutics until March 2016, where he left to pursue new opportunities, leading to his founding of CiVi.

Thomas Tuschl, Ph.D. Dr. Thomas Tuschl is a Professor of RNA Molecular Biology at Rockefeller University. Dr. Tuschl is world renown for his research on the regulation of RNA and has discovered small interfering RNAs (siRNAs), microRNAs (miRNAs) and piwi-interacting RNAs (piRNAs). He is a member of the German National Academy of Sciences and the recipient of numerous awards, including the NIH Directors Transformative Research Project Award, the Ernst Jung Prize, the Max Delbrck Medal, the Molecular Bioanalytics Prize, the Meyenburg Prize, the Wiley Prize and the AAAS Newcomb Cleveland Prize. He is also the co-founder and a former Director of Alnylam Pharmaceuticals (NASDAQ: ALNY).

About Ceptur Therapeutics, Inc. Headquartered in Hillsborough New Jersey, Ceptur Therapeutics is a pre-clinical stage biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology. For more information about Ceptur Therapeutics, please visit http://www.cepturtx.com or follow http://www.linkedin.com/company/ceptur-therapeutics/ on Linkedin.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005064/en/

Excerpt from:
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology - BioSpace

Posted in Molecular Genetics | Comments Off on Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology – BioSpace

SwabSeq: Scalable, Sensitive and Fast COVID-19 Testing – UCLA Newsroom

Posted: January 20, 2022 at 2:01 am

After much of Los Angeles went dark in the spring of 2020 amid the growing SARS-CoV-2 threat, two UCLA scientists and their small teambegan working late nights on the fifth floor of the Gonda (Goldschmied) Neuroscience and Genetics Research Center, developing technology that would pave the way for the UCLA community to safely return to campus.

The safer-at-home orders had shut down all but the few core campus activities and services deemed essential. While that meant the suspension of most laboratory research, it didnt apply to a new project led by Valerie Arboleda M.D. 14,Ph.D. 14, assistant professor of pathology and human genetics, and Joshua Bloom 06, a research scientist in human genetics and an adjunct professor in computational biology. Through their collaboration with Octant Bio, a biotech company founded and incubated at UCLA; faculty in UCLAs departments of human genetics and computational medicine; UCLA Health; and other academic institutions across the country, their research ultimately found its way from the high-tech lab Arboleda and Bloom named SwabSeq to vending machines across campus.UCLA faculty, staff and students returning last fall were able to easily access the free COVID-19 test kits, with picking up a testas simple as grabbing a snack: Users simply register for the SwabSeq test by scanning a QR code with their smartphone, retrieve the kit and collect their saliva sample, then deposit the kit in a drop box next to the machine. An email or text notifies them when they can access a secure website for their result.

Diagnosing COVID-19 typically involves polymerase chain reaction (PCR) testing, but as a tool for mass screening of asymptomatic individuals, the approach is limited in its capacity. To run tens of thousands of tests simultaneously, SwabSeq harnesses the power of next-generation DNA sequencing a revolutionary technology thats come of age in the last 15 years and enables the processing of millions of DNA fragments at a time. The testing platform also bypasses a step typically required in the PCR method that of extracting RNA from samples, which can take days to process.

Im thrilled that SwabSeq helped put us back on campus and that my students and I are able to come into the lab.

Valerie Arboleda

SwabSeq attaches a piece of DNA that acts like a molecular barcode to each persons sample, enabling the labs scientists to combine large batches of samples in a genomic sequencing machine. Viewing the barcodes in the resulting sequence, the technology can quickly identify the samples that have the coronavirus that causes COVID-19. SwabSeq can return individual test results in about 24 hours, with highly accurate results the false-positive rate is just 0.2%.

Michal Czerwonka

Rachel Young, laboratory supervisor and clinical laboratory scientist for the COVID-19 SwabSeq lab

SwabSeq has now tested more than half a million specimens from UCLA, as well as from a handful of other universities in Southern California and from the Los Angeles Unified School District. A $13.3 million contract recently awarded by the National Institutes of Health sets the stage for an expansion of SwabSeqs efforts.

This is an innovative use of genomic sequencing for COVID-19 testing that is uniquely scalable to thousands of samples per day, [and that is] sensitive and fast a combination that is challenging to find in diagnostic testing, Arboleda says. Its not cost-effective as a test for a few people, or if you have someone in the hospital who needs an immediate result, but its very effective as a screening tool for large asymptomatic populations.

Neither Arboleda nor Bloom could have predicted they would one day find themselves leading a major element of UCLAs research response to a once-in-a-century pandemic.

Arboleda entered the David Geffen School of Medicine at UCLA intending to become a full-time clinician, but when she took a year off from her medical school studies to work in a lab, she found her true calling. She enrolled in the UCLA Medical Student Training Program, graduating in 2014 with both an M.D. and a Ph.D. in human genetics. As a faculty member, she now devotes about 80% of her time to research, with much of the focus on rare genetic syndromes.

Bloom, trained as a geneticist and a computational biologist, has used model systems such as yeast to develop experimental and computational methods for identifying the heritable genetic factors underlying gene expression differences and other complex traits in large populations. Ive worked on some really abstract problems. Diagnostic testing in a pandemic is definitely not something I thought Id ever be involved in, he says, smiling.

Michal Czerwonka

A machine in the SwabSeq laboratory

Like most of their UCLA colleagues and much of the rest of the world, Bloom and Arboleda saw their work routines upended by the pandemic. Bloom was grappling with the new reality when he received a call from Sri Kosuri, a UCLA assistant professor of chemistry and biochemistry and co-founder/CEO of Emeryville, California-based Octant Bio, the startup where Bloom was a consultant and where early pilot studies for SwabSeq were conducted.

He suggested we could turn the drug-screening technology Octant was using into a COVID test, and asked if I could help with the computational work, Bloom recalls. There were other people at UCLA who were also thinking that with all these smart people here, we should be able to develop a test. From there we began to have large group meetings involving multiple universities sharing information.

When Arboleda heard about the nascent project from a faculty colleague, she knew she could be helpful. In addition to the expertise in molecular biology she could apply to setting up the experiments, her training in pathology gave her the experience with regulatory matters that would need to be addressed once the test was developed. She agreed to collaborate with Bloom, who used his expertise in informatics to optimize the automated DNA sequencing process toward the goal of producing accurate diagnostic readouts.

The two spent a good part of April and May 2020 in the lab. We would do the assay and put it on the sequencer, then Josh would analyze it as soon as it came off the machine, Arboleda says. Based on that, the next day we would adjust a couple of parameters and rerun the experiment.

PreCOVID-19, she had become accustomed to a supervisory role as a principal investigator overseeing a team of scientists. I hadnt gone back to the lab in a while, she says. It was a wild two months, where I felt like a grad student again!

The number and pace of the iteration cycles a new one every 24 hours made this research project unlike any other Bloom had seen. The sequencing technology enables that, because you can tweak a bunch of things and get readouts for them all at once, he says.

But more than that, he credits the speed with which SwabSeq moved from concept to reality to an all-hands-on-deck approach befitting the urgency of the need. We had senior faculty, including department heads, engaged and excited to help, Bloom says.

One of those department heads isEleazar Eskin,chair of the Department of Computational Medicine,a departmentaffiliated with both UCLA Samueli School of Engineering and the medical school. He hascoordinatedlogistics and business operations to ensure that the lab operates efficiently and remainsflexibleenough toadapt to changing circumstances, such asthe appearance of theomicron variant of the virus.Eskinalso built the custom software for SwabSeq'slab-information management system.

Adds Arboleda: Everyone knew it was important and contributed in whatever way would support the mission, whether it was getting space, fundingor institutional review board approvals. And since only people who were doing COVID work could come to campus, I had people on my team who said, OK, Ill put on a mask and do whats needed.

Michal Czerwonka

Hard at work in the SwabSeq lab

The SwabSeq lab now occupies an entire floor in the Center for Health Sciences South Tower. The space is divided into three rooms, each dedicated to a portion of the test. One room is for handling samples; a second is used as a clean room and storage area; and a third, its walls lined with high-level sequencers, is for post-PCR sequencing. All over, freezers and refrigerators store enough reagents for millions of tests. The lab isnt necessarily a one-off Arboleda notes that the technology can be applied to general infectious disease testing and surveillance. Its flexible protocol can rapidly scale up testing and provide a solution to the need for population-wide testing to stem future pandemics, she says.

For now, aside from regular meetings to discuss SwabSeq development and high-level technical issues, the scientists have returned to the work they were doing before everything changed in March 2020. Im thrilled that SwabSeq helped put us back on campus and that my students and I are able to come into the lab, Arboleda says. Now if someone tests positive, no one worries because that person can stay home, and we know we can all easily get tested.

See the original post:
SwabSeq: Scalable, Sensitive and Fast COVID-19 Testing - UCLA Newsroom

Posted in Molecular Genetics | Comments Off on SwabSeq: Scalable, Sensitive and Fast COVID-19 Testing – UCLA Newsroom

CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world’s largest organizations dedicated to…

Posted: January 20, 2022 at 2:01 am

Combined group to enable better public health outcomes through innovation in diagnostics and laboratory informatics technology

TUCSON, Arizona, Jan. 18, 2022 /PRNewswire/ -- CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys.This acquisition and Sunquest combination creates one of the world's largest organizations dedicated to diagnostic and laboratory informatics.

CliniSys' vision is to go beyond the walls of the clinical laboratory to embrace a new wave of digital diagnostics and laboratories across the continuum of care and community to improve public health. HORIZON Lab Systems is critical to this vision with its advanced cloud-based laboratory solutions and unsurpassed knowledge and expertise in Environmental, Water Quality Testing, Public Health, Toxicology and Agriculture laboratory solutions.

Together, CliniSys, Sunquest and HORIZON Lab Systems are over 1,300 employees living in 12 different countries, representing 19 diverse cultures, speaking 21 different languages with unsurpassed global knowledge of the complex laboratory and diagnostics sector.

CliniSys is positioned to deliver the benefits of cloud transformation and apply new technologies such as advanced analytics, AI, and machine learning, to empower laboratory professionals with better diagnostic capabilities and tools to work more effectively and improve public health worldwide.

Laboratories around the globe monitor and safeguard health across multiple determinants of health from medical care, genetics, environmental to physical influences and CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe.

Michael Simpson, CliniSys CEO, commented, "Public health is a major concern for all governments and citizens.With HORIZON's advanced cloud-based solutions and unsurpassed knowledge and expertise in Environmental, Water Quality Testing, Public Health, Toxicology and Agriculture, CliniSys can now provide organizations and governments at all levels, and across different sectors of the public health ecosystem, solutions to improve health at population scale."

About CliniSys

CliniSys, headquartered in Chertsey, England and Tucson, Arizona, is one of the largest providers of laboratory information systems, order entry and result consultation, and public health solutions in disease surveillance and outbreak management across the United Kingdom, Europe, and the United States.For 40 years, successfully specializing in complex and the wide scale delivery of comprehensive laboratory and public health solutions in over 3,000 laboratories across 34 countries using CliniSys solutions.

Our combined cross-discipline expertise provides customers with solutions to support laboratory workflow across clinical, histology, molecular, genetics, including order management, reporting and results delivery.Additionally, we serve laboratories in environmental testing, water quality, agriculture, and toxicology.

http://www.clinisys.com(UK & Europe)

http://www.sunquestinfo.com(North America)

http://www.horizonlims.com(HORIZON)

CliniSys Media Contact:

Linden GregoryMetia Group+44 (0) 7525 926 435 [emailprotected]

SOURCE CliniSys

Read the original here:
CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world's largest organizations dedicated to...

Posted in Molecular Genetics | Comments Off on CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world’s largest organizations dedicated to…

Conservation of magnetite biomineralization genes in all domains of life and implications for magnetic sensing – pnas.org

Posted: January 20, 2022 at 2:01 am

Significance

We present a model of biogenic magnetite formation in eukaryotes and hypothesize this genetic mechanism is used by broad forms of life for geomagnetic sensory perception. Countering previous assertions that salmon olfactory tissues lack biogenic magnetite, we determine that it is present in the form of compact crystal clusters and show that a subset of genes differentially expressed in candidate magnetoreceptor cells, compared to nonmagnetic olfactory cells, are distant homologs to a core suite of genes utilized by magnetotactic bacteria for magnetite biomineralization. This same core gene suite is common to a broad array of eukaryotes and the Asgard clade archaea Lokiarchaeta. Findings have implications for revising our understanding of eukaryote magnetite biomineralization, sensory perception of magnetic fields, and eukaryogenesis.

Animals use geomagnetic fields for navigational cues, yet the sensory mechanism underlying magnetic perception remains poorly understood. One idea is that geomagnetic fields are physically transduced by magnetite crystals contained inside specialized receptor cells, but evidence for intracellular, biogenic magnetite in eukaryotes is scant. Certain bacteria produce magnetite crystals inside intracellular compartments, representing the most ancient form of biomineralization known and having evolved prior to emergence of the crown group of eukaryotes, raising the question of whether magnetite biomineralization in eukaryotes and prokaryotes might share a common evolutionary history. Here, we discover that salmonid olfactory epithelium contains magnetite crystals arranged in compact clusters and determine that genes differentially expressed in magnetic olfactory cells, contrasted to nonmagnetic olfactory cells, share ancestry with an ancient prokaryote magnetite biomineralization system, consistent with exaptation for use in eukaryotic magnetoreception. We also show that 11 prokaryote biomineralization genes are universally present among a diverse set of eukaryote taxa and that nine of those genes are present within the Asgard clade of archaea Lokiarchaeota that affiliates with eukaryotes in phylogenomic analysis. Consistent with deep homology, we present an evolutionary genetics hypothesis for magnetite formation among eukaryotes to motivate convergent approaches for examining magnetite-based magnetoreception, molecular origins of matrix-associated biomineralization processes, and eukaryogenesis.

Diverse animals utilize the Earths magnetic field for orientation and navigation cues; however, the receptor mechanism that underlies this sensory ability remains a fundamental question in sensory biology (13). A leading hypothesis posits that specialized sensory organelles containing crystals of magnetite physically interact with Earthstrength magnetic fields to transduce geomagnetic information into neural signals (1, 47). These crystals are predicted to be similar in shape and size (47) to iron mineral crystals biosynthesized by magnetotactic bacteria (MTB) for use in magnetotaxis, passive alignment to geomagnetic fields (8). MTB are the most ancient and simple organisms known to biomineralize (79), with biologically controlled iron-based (Fe3O4 and Fe3S4) iron mineral formation in the domain Bacteria proposed to have originated 3 to 2 gigaannum (Ga) (911). Magnetite biomineralization thus predates the emergence of the crown group of eukaryotes (1.8 to 1.2 Ga), based on the fossil record and molecular clock estimates (7, 912). Like other forms of nonskeletal biomineralization, formation of crystals occurs in intracellular compartments bounded by membranes, underpinned by local expression of genes that guide precipitation (13). The mechanisms that control magnetite biomineralization in prokaryotes have been studied for decades, and numerous associated proteins are well characterized (1417).

Presence of magnetite in eukaryotes has mainly been affirmed through magnetic remanence measurements in magnetosensitive species, e.g., honeybees, birds, mice, fish (reviewed by ref. 6), yet direct evidence for intracellular magnetite is scant, the evolutionary origins are poorly understood, and no magnetite-based receptor has been confirmed in situ (1, 18, 19). Iron-rich structures detected in the upper beak of pigeons were once proposed as magnetoreceptors (20) but later were identified as phagocytosed debris in cells presenting major histocompatibility complex II, probably macrophages(18). Still, multiple lines of evidence support a universal magnetite-based magnetoreceptor (4, 5): The trigeminal nerve of fish exhibits neural responses to magnetic treatment (4), neurons associated with the avian trigeminal brainstem complex show magnetic activation (2), and behavioral responses to pulse magnetization are exhibited by birds, sea turtles, and bats (2123). Thus, the magnetite hypothesis for geomagnetic receptivity holds and is believed to provide sensory information that differs from the cryptochrome-based model, which is unaffected by magnetic pulse (3).

Pacific and Atlantic salmon (Oncorhynchus and Salmo) possess an innate guidance mechanism utilized for long-distance migration and homing to natal rivers (24). Navigational cues include geomagnetic intensity and inclination, as shown by exposing juvenile salmon to simulated magnetic displacements (25, 26). Although magnetite is present in salmon tissues, no deposits have been directly associated with sensory transduction and in most cases are unlikely to represent the magnetoreceptor site (6). An important exception is occurrence of magnetite in olfactory epithelial tissue (refs. 1, 5, and 27; but see ref. 19), innervated by the magnetically responsive superficial ophthalmic branch of the trigeminal nerve (4). We extend the hypothesis that magnetite-containing cells have a universal genetic basis and role in magnetoreception through 1) in situ magnetic measurements, microscopies, and transcriptomic characterization of magnetite-containing cells of salmonids; 2) assessing whether magnetite biomineralization in eukaryotes could have ancient prokaryotic origins by comparing the genome contents of a salmon, 12 additional eukaryotes, and one archaea against an MTB magnetosome protein sequence database; and 3) proposing an evolutionary genetics hypothesis for eukaryote biomineralization and magnetoreception predicated on transcriptomic and comparative genomic findings.

The physical properties of magnetite in salmon olfactory epithelium were characterized using a combination of ferromagnetic resonance spectrum (FMR) and atomic and magnetic force microscopies (AFM/MFM). The FMR analysis, conducted on intact olfactory rosette (OR) tissues (Fig. 1A), provides in situ information relating to the size and physical arrangement of magnetite particles. The rainbow trout (Oncorhynchus mykiss) broad FMR spectrum (Fig. 1B; SI Appendix, Fig. S1) seen in the electron spin resonance spectrum is different from that reported for linear chains of magnetosome crystals in MTB and rather resembles the FMR spectra of strongly interacting magnetic particle systems (28). Consistent with that finding, visualized under AFM, magnetic particles extracted from digests of Atlantic salmon (Salmo salar) olfactory epithelium appear as uniformly sized and ellipsoid shaped clusters, with each cluster containing a compact arrangement of individual particles. Clusters range in size from 200 to 300 nm (Fig. 1 CG) and are estimated to contain 100 to 200 individual particles with diameters that range from approximately 30 to 60 nm. As an example, a profile of a single cluster (Fig. 1D) marked by the white bar in Fig. 1C, is 300 nm in diameter and contains crystals with a maximum diameter of 60 nm. Individual crystals can also be visualized in the higher resolution image shown in Fig. 1E. Using images taken from a different sample location, to demonstrate the magnetic properties of particle clusters, a switch from AFM (Fig. 1F) to MFM measurements performed in a near-zero field show an attractive interaction between the magnetic probe tip and the magnetite, which results from magnetostatic interactions and is indicated by a dark contrast (Fig. 1G; SI Appendix, Fig. S2). Our images of magnetite are strikingly similar to those obtained by Diebel etal. (5) (see their figure 2), who used confocal microscopy and AFM/MFM to visualize a cluster of intracellular magnetite in a rainbow trout olfactory epithelium cell. In our case, we can rule out bacteria and commercially prepared magnetite contaminants by differences in particle size and aggregation patterns visualized by AFM/MFM (SI Appendix, Figs. S2 and S3).

Candidate magnetoreceptor cell characteristics. (A) Schematic representation of a salmonid head showing OR location. (B) Broad electron spin resonance spectrum of rainbow trout (O. mykiss) ORs demonstrates presence of ferromagnetic material. The sharp edge at a magnetic field strength H = 3 kOe corresponds to a paramagnetic signal (SI Appendix, Fig. S1). (C, E, and F) AFM images of magnetite clusters extracted from Atlantic salmon (S. salar) ORs (SI Appendix, Fig. S2). (D) Dimensional profile of the magnetite cluster (x axis) and maximum diameter of individual magnetite particles (y axis) marked by the white line in (C). (E) Individual particles can be visualized under higher magnification. (G) Magnetic force microscopy image obtained at 0.5 mT; image directly corresponds to F. (HJ) Chinook salmon (O. tshawytscha) transcriptome profiles of three blood, muscle, and whole OR samples obtained from three fish (n = 9 transcriptomes), a single pair of deep-sequenced ORs (ORds) sampled from a fourth fish (n = 1 transcriptome), and MAG and NM cells obtained through three replicate MAG cell isolation experiments, each using dissociated ORs from 3 to 5 fish (n = 3 MAG and n = 3 NM transcriptomes). (H) Multidimensional scaling plot and (I) heatmap of top 500 most abundantly expressed genes across the 16 transcriptomes. ORs in the color keys are demarcated with dark outlines. (J) M (log ratio) versus A (mean average) plot of the log2 fold ratio of modeled gene expression values (y axis) and average log2 counts per million (x axis) between magnetic (negative y axis) and nonmagnetic (positive y axis) cell isolates, with red dots indicating DEGs (at FDR < 0.05) and black dots indicating no significant difference in gene expression.

After confirming the presence of biogenic magnetite in salmonid olfactory epithelium, we then determined candidate magnetoreceptor genes of Chinook salmon (Oncorhynchus tshawytscha) by contrasting transcriptome profiles of magnetic (MAG) and nonmagnetic (NM) olfactory cells and blood and muscle tissues. Briefly, three replicate MAG cell isolation experiments were conducted by dissociating OR cells, followed by collection of MAG cells using a magnet with a pointed tip placed on the outside, upper portion of the sample vial and allowing the NM cells to settle to the bottom of the vial through gravitational forces. The pellet of MAG cells that accumulated inside the vial at the tip of the magnet and NM cells from the bottom of the vial were aspirated and transferred into new vials for messenger RNA (mRNA) isolation. Because of MAG cell scarcity, three to five sets of ORs were combined for each cell isolation experiment. The MAG and NM samples, plus three sets of ORs, blood, and muscle tissues from three additional fish and a set of ORs from a fourth fish (for a total of 16 transcriptomes), were subjected to Illumina sequencing for transcriptome profiling. Adjusting for false discovery rates (FDRs) < 0.05, this experiment revealed 610 differentially expressed genes (DEGs) more highly expressed in the MAG relative to the NM cell type and considerably greater difference between MAG and blood and muscle tissues (Fig. 1 HJ; SI Appendix, Fig. S4 and Table S1). In the latter two cases, >11,000 DEGs were more highly expressed in each binary comparison. Consistent with DEG results, multidimensional scaling plots show well separated clusters of points by tissue type or experimental condition (Fig. 1H). Two of the three MAG samples clustered together, positioned distinct from their NM sample counterparts, while the third MAG sample grouped between the other MAG samples and its NM experimental counterpart. The NM samples were positioned intermediate between the MAG and nontreated olfactory samples. A heatmap of the top 500 most variable genes shows that at this high level, samples from MAG and NM experimental trials group together (Fig. 1I), which masks expression differences between these two OR cell subtypes. Overall, differences in gene expression fold-differences and transcript abundance are less for the MAGNM contrast compared to MAGblood and MAGmuscle contrasts, as visualized in MA plots, in which red and black dots depict genes with significant or nonsignificant levels of expression, respectively (Fig. 1J MAGNM contrast; MAGblood and MAGmuscle contrasts available in SI Appendix, Fig. S4).

Discrete differential gene expression distinctions observed repeatedly when comparing MAG and NM cell findings in our study are only consistent with the conclusion that salmon olfactory tissue magnetic properties result from the intracellular presence of biogenic magnetite. With macrophages ruled out (SI Appendix), a random assortment of MAG material attached to NM cells could not provide the data observed here.

To broadly characterize the molecular functions of MAG cells, we relaxed the threshold FDR < 0.1 and focused on the 1,588 DEGs more highly expressed within the MAG sample contrasted to the NM sample. These candidate genes were overrepresented in 80 Gene Ontology (GO)categories, including anatomical structure and cell maturation/development, mitotic cell cycle, protein modification, protein binding, and bounding membrane of an organelle (Dataset S1). Among the DEGs were proteins involved in iron uptake and transport (14, <1% of DEGs) and iron ion binding (6, <1% of DEGs), including ferritin. Also present were proteins associated with keywords actin (84, 5.3% of DEGs), microtubule (24, 1.5% of DEGs), and cytoskeleton (36, 2.3% of DEGs). These results are consistent with the production or maintenance of an organelle, possibly one produced through a cellular machinery process that somehow shares commonalities with mitosis and that involves iron.

To examine the hypothesis that genetic mechanisms controlling magnetite biomineralization in prokaryotes and eukaryotes might share common, ancient origins, we compared the genome contents of 13 eukaryotes (five protostomes and eight deuterostomes; SI Appendix, Table S2) to a database of magnetite biomineralization genes (Dataset S2). We found that 11 MTB magnetosome gene homologs (MGHs) are universally present (uMGHs) in eukaryotes, defined as having bidirectional Basic Local Alignment Search Tool protein (BLASTp)matches across at least 12 of the 13 animal genomes (>92%, Fig. 2A and Datasets S2 and S3). Furthermore, 9 of these 11 uMGHs were contained in genome contents of the Asgard archaea clade Lokiarchaeota (Fig. 2A; Datasets S2 and S3), which shows monophyly with eukaryotes (29, 30). The MamE homolog, an HTRA-like serine protease, exhibits exceptionally high levels of conservation in Chinook salmon and other magnetically sensitive animals (Fig. 2; Dataset S4 and SI Appendix).

Comparative genomics. Data are presented for reciprocal BLASTp matches between magnetotactic bacterial biomineralization proteins and genome contents of eukaryotes and the archaea Lokiarchaeota. (A) Numbers of eukaryote proteins with reciprocal BLASTp match to 11 proteins known for involvement in prokaryote iron biomineralization (numbers of genes in prokaryote database in parenthesis). (BG) Scatterplots of alignment lengths and percent identities scores for unidirectional BLASTp matches between genome contents of five magnetic responsive eukaryote taxa and the MTB magnetosome gene dataset (gray background circles). Proteins showing homology to the MTB gene MamE (HtrA-like serine protease) with E-value < 1 10e5 are color highlighted. (B) All taxa (CG combined), (C) zebra finch, Taeniopygia guttata (red); (D) naked mole-rat Heterocephalus glaber (cyan); (E) Chinook salmon, O. tshawytscha (blue); (F) little brown bat, Myotis lucifugus (black); and (G) honeybee, Apis mellifera (yellow). (H) A partial (66 amino acid) MamE alignment displays high levels of conservation across the five eukaryote taxa (CG) and four MTB (1 to 4: UniprotKB accessions L0R6S4, Desulfamplus magnetovallimortis; C5JBP1, uncultured bacterium; A0A0F3GW16, Candidatus Magnetobacterium bavaricum; C5JAJ2, uncultured bacterium). Arrows in panels C to G point to the gene included in the multispecies alignment, with the red arrow indicating a gene differentially and more highly expressed in salmonid candidate magnetoreceptor cells, indicated by e* in the alignment. A full alignment is available from Dataset S4. Genome details are available from SI Appendix, Table S2.

A previous survey of MTB Nitrospirae and Proteobacteria genomes indicates they share a core set of five MTB magnetosome genes, MamABEKP (10). The 11 uMGHs identified in our study include four of these five core genes, with only MamP missing from eukaryotes (and Lokiarchaeota; Fig. 2A; Dataset S3). MamP contains an iron-binding residue with a role in iron oxidation (31), but this protein is not essential for crystal formation, possibly because of functional compensation by other magnetosome proteins (15, 31). These core genes, along with MamH and MamN (6 of the 11 uMGHs), are part of the MamAB operon (1416), the only operon solely capable of supporting magnetite crystallization (14, 17). We found no support for the presence of MGHs belonging to three other magnetosome-associated, operon-like gene clusters, MamGFDC, MamXY, and mms6 (Datasets S2 and S3). Those gene clusters are generally present in magnetotactic Alphaproteobacteria (14, 17, 32) but absent from magnetotactic Deltaproteobacteria and Nitrospirae (10, 16, 33) (Datasets S2 and S3). Of the remaining five uMGHs, Mad9, 17, 25, 29 are present in genomes of magnetotactic Deltaproteobacteria and Nitrospirae, the latter also containing Man6 (10, 16). At a broader view, a meta-analysis of MTB genomes indicated that Mad genes are present in Nitrospirae, Omnitropha, and Deltaproteobacteria but absent from Proteobacteria classes Alpha, Eta, and Zeta and that Man genes are only contained in genomes of Nitrospirae (34). Thus, presence of the Man6 uMGH in eukaryote genomes, in conjunction with generally high proportions of eukaryote gene matches to individual Nitrospirae MTB proteins (SI Appendix, Table S3), is most parsimonious with a magnetite biomineralization gene transfer to eukaryotes having involved a Nitrospirae ancestor.

After identifying the 11 universally conserved uMGH proteins, we then cataloged their complete repertoire (homologs and paralogs) within genomes of zebrafish (Danio rerio) and Chinook salmon, which amounted to a total of 244 and 367 genes encoding uMGHs. Of those Chinook salmon genes, 332 matched to 181 zebrafish orthologs and corresponding Zebrafish Information Network (ZFIN) gene codes (35), a 45% reduction most likely explained by salmonids whole genome duplication event (36). In contrast, the zebrafish gene dataset was only marginally reduced (to 226 ZFIN gene codes) after accounting for a small number of paralogs. The number of fish genes encoding uMGHs varied across the 11 uMGH categories, with MamA, MamE, and MamK having the greatest number of matches (Table 1). Using PANTHER (37) and ZFIN gene codes to leverage the well-annotated zebrafish genome (35), notable protein classes included oxidoreductase, protein chaperones, matrix proteins, serine proteases, and transporters. Despite the diversity of protein classes, gene ontology analysis for these two sets of fish uMGHs indicated significant overrepresentation and exceptionally high fold-enrichment values across several categories; as an example, the molecular function term protein folding chaperone is 90 enriched in zebrafish and 63 enriched in Chinook salmon. Other notably enriched ontology categories include protein folding and refolding; divalent inorganic cation transmembrane transporter activity; four iron, four sulfur cluster binding; zinc ion transport, activity, and response; cellular response to heat (mostly heat shock proteins); and actin-based cell projection (SI Appendix, Table S4; hierarchical ontologies available from Dataset S5). Consistent with these findings, significantly overrepresented reactome pathways include zinc efflux and compartmentalization by the SLC30 family; signal transduction; laminin interactions; and the anaphase promoting complex/cyclosome, which regulates progression through the mitotic phase of the of the cell cycle (38). Several magnetite biomineralization proteins of bacteria have been functionally categorized, yet the roles of some proteins are not yet well understood, especially within the magnetotactic Nitrospirae and Deltaproteobacteria (Table 1). A list of genes encoding fish uMGHs, their ZFIN codes, and protein class annotations are provided in Dataset S6.

Summary data for the complete repertoire of fish genes encoding distant homologs of 11 MTB biomineralization proteins

Considering the full repertoire of uMGHs in Chinook salmon, we then examined whether these genes may be engaged with putative magnetite presence in salmonid olfactory cells, and thus biomineralization, in light of the DEG findings at threshold FDR < 0.1. Based on the full repertoire of protein-coding uMGHs in the salmon genome, 12.5 MGHs are expected to occur by chance in a random sample equally sized to the MAG DEG dataset. We found 18 uMGHs were among the differentially expressed genes, which approaches statistical significance (P = 0.0675, one-tailed proportion test, P value threshold = 0.05). This indicates that uMGHs may show up-regulated expression in the MAG cell sample. The 18 genes were distributed across 7 of the 11 universally conserved categories and included MamABEK, Mad9, Mad25, and Man6 (SI Appendix, Table S5 and SI Appendix). The differentially expressed MamE homolog shows an exceptional level of conservation to MTB proteins (Fig. 2 E and H; Dataset S4).

The widespread distribution of magnetite and retention of distant homologs of bacterial magnetite biomineralization genes in eukaryote genomes is interpreted by us as an indication that biologically controlled magnetite precipitation is a fundamental feature of eukaryotic biology and was at one time present in the last common ancestor of extant eukaryotes and some archaea. All but two of the core set of genes we identified as universally present in eukaryotes are detectible in genome contents of Lokiarchaeota, a member of the Asgard superphylum of archaea that forms a monophyletic group with eukaryotes in phylogenomic analyses and whose genome encodes an expanded repertoire of eukaryotic signature proteins (actin and tubulin, which form the core of the cytoskeleton), suggestive of sophisticated membrane remodeling capabilities (29, 30). Our results are thus consistent with eukaryotes having evolved from within the archaea (3942).

Could ancient serial endosymbiosis events explain magnetite biomineralization in complex life forms (9, 43) (Fig. 3)? Since the now widely accepted symbiotic origin for some eukaryotic organelles was proposed, a wealth of secondary and even tertiary symbioses events within eukaryotes have been cataloged (reviewed by refs. 44, 45). Here, observed commonality of core biomineralization genes between prokaryotes and eukaryotes is consistent with an ancient endosymbiosis event (9), although an ancient horizontal gene transfer event cannot be ruled out. Regardless of gene acquisition mechanisms, retention of uMGHs in eukaryote genomes (and Lokiarchaeota) signifies that these particular genes are essential features of eukaryotic biology. Our results are parsimonious with the hypothesis that magnetite biomineralization represents deep homology, a latent but plesiomorphic ability (genetic and cellular) to form structures (46), and exaptation of magnetite biomineralization for magnetoreception (7, 43).

Conceptual schematic of the magnetite evolutionary hypothesis. The timing of ancient serial endosymbiosis events (stylistically adapted from ref. 45) are detailed in refs. 9, 10, and 12 and described in the main text. Uncertainty surrounding timing of eukaryogenesis is depicted by the box.

The importance of endosymbiosis in the evolution of eukaryotic complexity has become firmly established through accumulation of evidence that mitochondria and plastids (double bilayer membrane-bound organelles) evolved from bacteria (44, 45). A necessary intermediary to endosymbiosis is formation of obligate hostsymbiont associations, with numerous examples known to occur at various levels of interdependence and integration, e.g., endosymbiotic bacteria found in cells of insects, nitrogen-fixing spheroid bodies found in some diatoms, and zooxanthellae in marine invertebrates (47). Symbiosis is suspected to occur between members of the Asgard clade of archaea and a candidate division of bacteria (TA06) (40) and was recently documented to occur between MTB and a unicellular eukaryote. In that case, excavate protists (Symbiontida, Euglenozoa) and ectosymbiotic Deltaproteobacteria biomineralizing ferrimagnetic nanoparticles formed a mutualistic relationship based on collective magnetotactic motility with division of labor and interspecies hydrogen-transferbased syntrophy (48). These assemblages were identified in multiple locations around the northern and southern hemispheres of the globe, and congruence in topology of hostsymbiont phylogenetic trees indicates that these partners coevolved and diversified from a single ancestral magnetotactic symbiosis event. Symbiosis between MTB and other forms of life potentially carry a selective advantage, perhaps through a dedicated molecular machinery to sequester excess iron, or perhaps through the physical properties of magnetite, be it a magnetic dipole moments for magnetotaxis of the host [as suggested for a marine protist (48) and for larvae of a marine mollusc (49)], density for adjusting buoyancy in the water column, mechanical stability similar to silica-based phytoliths in grasses and other land plants, hardness for providing protection against grazing, or protection against ultraviolet radiation (50). Consistent with endosymobiosis, mutualistic symbiosis assemblages composed of microbial eukaryotes and bacteria that biomineralize magnetosomes have been observed in multiple locations around the globe (48).

Previous searches for candidate magnetoreceptors in dissociated salmonid ORs using a microscope with an applied rotating magnetic field identified cells with magnetic properties (27). However, in a follow-up study (19), cells isolated in a similar way showed an absence of intracellular magnetite and presence of extracellular contaminants, leading some researchers to question whether olfactory tissues indeed even harbor biogenic magnetite at all (51). Why our search for magnetite was successful in contrast to the cell-spinning approach may be explained by the constraining effect of solution viscosity on spinning properties, with trade-offs between levels of dissociation. Gentle dissociation produces whole cells as necessary for quantifying intracellular components but increases the probability of cells remaining in intact clumps that may not spin, while strong dissociation risks membrane rupture and loss of magnetic contents that are invisible under light microscopy. Alternatively, putative magnetic particle structures from ruptured trigeminal nerve terminals in the OR were released into the cell suspension and adhered to other cells, making them magnetic.

Our findings are a transformative advance to generate convergent approaches that may illuminate the mysterious sixth sense of magnetoreception. Equipped with genomic findings, genetic tools coupled with those of physics, behavior, anatomy, and physiology can be developed to validate associations between candidate magnetoreceptor cells and neural signal transduction. Whether the ancient biomineralization system we nominate here bears a relationship to the numerous other matrix-mediated biomineralization systems found in living organisms (7, 13) or played a role in eukaryogenesis further warrants advancing convergent approaches to resolve the complex innovations that embody lifes diversity.

To minimize contamination by nontarget magnetic particles, the tools used for animal termination and dissection were iron-free and nonmagnetic (made of titanium, ceramic, or glass). All tools and labware used for microscopy protocols, if not presterilized, were cleaned in HCl or ultrasonic bath in EtOH. The tools and labware used for magnetic cell isolation/transcriptomics experiments were cleaned in HCl, with the exception of filter tips used in RNA liquid handling. That work was performed inside a hood equipped with a high-efficiency particulate air filterwhenever possible, and tools were covered with plastic wrap as a dust preventative measure. All reagents were ultrapure, molecular biologygrade buffers made with Milli-Q water, and powdered (e.g., papain and L-cysteine [Sigma-Aldrich]) reagents were hydrated in molecular-grade water and filtered through a 0.22-m membrane using an HCl-cleaned syringe. Fish were obtained from local fish farms/markets or hatchery operations and killed in accordance with European and German regulations or under the authority of permit issued to Oregon State University (ACUP 4421).

To assess in situ magnetic properties, the olfactory epithelium of rainbow trout (O. mykiss, n = 10) was isolated bilaterally and frozen for measurement of FMR absorption spectra acquired using an X-band ESR spectrometer (JEOL, JES-FA 200), at a microwave frequency of 9.07 GHz, 4-mW input power, and a magnetic field sweep rate of 200 mT/min. For lock-in detection, the applied magnetic field was modulated with a 0.4-mT magnetic field of 100 kHz frequency. Findings were compared to experimentally observed FMR spectra of MTB quantitatively explained using the theoretical model developed in Charilaou etal. (52).

To study biogenic magnetism at the nanoscale, the physical and magnetic features of salmonid and bacteria magnetite particles were determined using a custom-designed scanning probe microscope with AFM and MFM modes. Biogenic magnetite particles were extracted from Atlantic salmon olfactory epithelium and the MTB Magnetospirillum gryphiswaldense MSR-1 and compared to a commercial ferrofluid (sample preparation details available from SI Appendix, Extended Methods). The scanning probe microscope (Veeco Digital Instruments) was equipped with a small, super-sharp AFM/MFM tip attached to a commercially produced cantilever (53). The tip, with a curvature radius less than 10 nm, was made from a microfabricated silicon probe selectively coated with 30 nm Co85Cr15. The tip and cantilever had a resonant frequency of 75 kHz and a spring constant of 3 N/m for measurement of topography and magnetic signals using MFM tapping and lift modes, setting the lift height in MFM measurements to 20 nm. External in-plane magnetic fields were generated by a pair of solenoids. The field strength was enhanced by a pair of iron cores, with a maximum field in the middle of two iron cores measured as 370 mT. The sweeping function of the magnetic field within the MFM was realized by the combination of a function generator (HP 33120A) and a self-made voltage to current converter with a maximum current of 8 A for the employed solenoid. The salmon magnetite sample was visualized in external fields applied normal (z axis) to the sample surface at field strengths of 0.5, 3.5, 7, 15, and 35 mT. The externally applied magnetic fields orients all particle magnetic moments partially or even completely along the field direction. Since the probe magnetization is also partially aligned, attractive magnetostatic interactions between probe and magnetic nanoparticles result. These interactions are specifically measured upon lifting the probe in the MFM mode of operation and they manifest themselves in terms of a dark contrast. In the tapping mode of operation, the oscillating probe is periodically almost in contact with the sample, which results in a topographical image irrespectively of the nanoparticle magnetic configurations. Additional microscope details are available from (53).

Rainbow trout olfactory epithelium and MTB were examined using reflectance mode of the confocal microscope, based on previously developed protocols (5, 54) and described in SI Appendix, Extended Methods. A sample of competent Escherichia coli (DH-5) was used as a nonmagnetic control. The MTB were obtained from mud samples collected in the Rhin Tortu, Strasbourg, France (483259.1N, 74538.0E). Samples were imaged using a Leica TCS SP5 II Laser Scanning Confocal microscope with a 63 oil immersion objective (numerical aperture 1.40). fn1-43fx was excited at 488 nm and emitted light collected using a 500 long pass filter. DAPI was excited at 405 nm. The reflectance mode option of the confocal microscope was calibrated using the MTB reflectance. Further analysis and image presentation were performed using ImageJ software (55). Confocal microscopy was performed at the invitro imaging core facility (CNRS UPS3156) located at the Institute of Cellular and Integrative Neuroscience, Centre National de la Recherche Scientifique, Strasbourg, France.

Tissues for RNA isolation were sourced from Chinook salmon reared in a single tank at the Fish Research Laboratory, Corvallis, OR (443352.4N, 231543.4W). 15 fish were sampled for OR tissues used in magnetic cell isolation experiments, one fish was sampled for OR deep transcriptome sequencing, and three fish were each sampled for muscle tissue, blood, and additional pairs of ORs. Muscle tissue was used as a negative control to rule out potential presence of contaminants during magnetic cell isolation experiments. For olfactory MAG and NM transcriptome profiling, three replicate experiments were conducted by enzymatically dissociating olfactory tissues, then isolating MAG cells by conducting magnetic collection (using a fine-point magnet placed on the exterior of a glass vial), during which NM cells collected on the bottom of the vial through gravitational forces (SI Appendix, Extended Methods). Given the scarcity of MAG cells in olfactory tissues, three to five sets of ORs were combined in each experiment to obtain sufficient material for visualization of the magnetic pellet under a dissecting microscope. The magnetic cell pellet was aspirated and placed in a RNase-free vial with 20 L buffer, followed by transfer of an aliquot (20 L) of the nonmagnetic cells to a separate RNase-free vial. All other transcriptome samplesn = 3 muscle, n = 3 blood, and n = 4 pairs of ORswere individually processed. The fish fork lengths ranged from 10 to 15 cm.

In the presence of QIAzol Lysis Reagent (Qiagen), solid tissues (untreated ORs and muscle) were mechanically homogenized and lysed with an electronic mortar and pestle, while blood and dissociated MAG and NM OR cells were homogenized and lysed by pipetting. Total RNA was isolated from lysed materials using a Qiagen RNEasy Mini kit following manufacturers protocols. Samples were submitted to Oregon State Universitys Center for Genome Research and Biocomputing core facility for messenger RNA isolation, Illumina library preparation, individual indexing for demultiplexing, and sequencing on an Illumina HiSeq2000. Each experimental pair of MAG and NM samples was sequenced in a single Illumina lane using 101 cycles and paired-end protocols, with one lane also including the additional snap-frozen single OR sample for deep sequencing. The other nine samplesblood, muscle, and OR tissueswere single-end sequenced in a single lane using 50 cycles.

The raw Illumina reads were quality processed with Trimmomatic (56) (version 0.32), removing adapter contaminants and low-quality sequences and retaining reads 25 nucleotides in length with an average sequencing quality of phred 20 across 4 nucleotide sliding windows. Reads were mapped with Bowtie2 version 2.2.1 (57) (setting: very sensitive) to a Chinook salmon reference transcriptome based on a Chinook salmon genome (36) having a total sequence length of 2.54 Gb (National Center for Bioinformatic Information Accession GCF_002872995.1). This genomes companion *rna.fna file contains 81,329 predicted RNA transcripts that correspond to 73,277 predicted proteins and their variants. The longest RNA transcript per gene (n = 47,921 transcripts) was selected for inclusion in the reference transcriptome used for read-mapping, differential gene expression analysis, and bidirectional BLASTp comparison to MTB biomineralization proteins (MTB accessions available from Dataset S3).

Differential gene expression was modeled using a generalized linear model likelihood ratio test implemented in EdgeR (58). With focus on MAG samples, pairwise contrasts were made to NM experimental counterparts, blood, and muscle tissues. Magnetoreceptors are presumed to be absent from the latter two sample types, and their expression profiles may be useful for making general inferences about gene functions. Data inputs for EdgeR included counts of mapped forward reads (to match single-end sequenced samples) extracted from *bam files. Transcripts were filtered for low expression using a minimum of two count-per-million reads across at least three of the 16 samples, adjusting for high expressed reads using trimmed mean of M componentread normalization (59). Postfilter, per-sample mapped read numbers ranged from 8.6 to 46.0 million (average 21.7 million; SD 9.0 million). A total of 38,598 (81% of 47,921) RNA transcripts were considered in differential gene expression analysis. Statistical significance was adjusted for multiple tests using BenjaminiHochberg (B-H) (60) FDR-corrected P values with a threshold cutoff of FDR < 0.05 for broad contrasts between MAG and all tissue types and FDR < 0.1 for analysis of genes differentially expressed in the MAGNM contrast. Broad relationships among gene expression profiles were visualized and inspected through multidimensional scaling plots (EdgeR function plotMDS) and heatmaps (gplot version 3.0.1 function heatmap.2) generated in EdgeR version 3.12.1 with R version 3.2 (61).

The molecular functions of zebrafish and Chinook salmon genes encoding uMGHs and genes differentially expressed in the MAG cell sample (contrasted to NM cell sample, FDR < 0.1) were annotated using the Protein ANalysis THrough Evolutionary Relationships classification system (37) (PANTHER version 13.1, release date February 3, 2018). To leverage well-characterized gene ontology terms from a model fish species, the Chinook salmon mRNA transcripts were BLASTx matched to zebrafish (D. rerio) orthologs (ENSEMBL genome version GRCz11, file Danio_rerio.GRCz11.pep.all.fa; last modified March 8, 2018) to identify PANTHER-compatible ZFIN identifiers (35). Nonspecific BLASTx matches were filtered by applying a threshold cutoff E < 1e5. Of the 1,588 MAG DEGs, 1,333 zebrafish ZDB gene identifiers were procured. Statistical tests for overrepresentation across GO complete categories (Overrepresentation Release 20181113; GO database release January 1, 2019) and reactome pathways (Reactome version 65, released June 12, 2018) were assessed on the basis of fold-enrichment values, dividing the observed by expected numbers of per GO or pathway term. This denominator is based on the zebrafish background genome and considers the number of genes in the input file. The zebrafish genome was used as a background genome. Statistical significance was adjusted for multiple tests using PANTHERs built-in B-H FDR correction function. Individual zebrafish and Chinook salmon genes encoding uMGHs (see below) were also categorized by PANTHER family/subfamily groups and protein classes, based on ZFIN identifiers (35), using the 2020_04 release of the ReferenceProteome dataset. Protein names of individual DEGs were also obtained from the Chinoook salmon RefSeq genome feature table (GCF_002872995.1).

Macrophages, a type of immune system cell that can precipitate and store iron deposits (62), were evaluated as a potential explanation for the observed magnetic properties of dissociated cells used for transcriptome experiments. Genes annotated as macrophage (n = 261 ZDB genes) in the ZFIN data repository (35) were matched to annotations for NM and MAG DEGs (at FDR < 0.05) and evaluated for statistical overrepresentation using a one-sided proportion test with a threshold significance value of P = 0.05.

Whether distant homologs of MTB biomineralization proteins are universally present among eukaryote genomes was assessed by comparing genome contents of 13 phylogenetically diverse eukaryote taxa (SI Appendix, Table S2) to a database of magnetosome proteins of distantly related phyla including Nitrospirae and Proteobacteria (classes Alpha, Delta, and Gamma; Uniprot-KB SWISS-PROT database download date 9/12/2018; search term name = magnetosome) (accessions provided in Dataset S3). An MGH was classified as universal (uMGH) in eukaryote genomes if a bidirectional BLASTp match to a named MGH occurred across at least 12 of the 13 eukaryote genomes (>92%), allowing for one missed protein product annotation or gene loss. Nonspecific matches were filtered by applying a threshold cutoff Expect value (E) of E < 1e3, considered reliable for inferring gene descendants with distant homology (63), in the eukaryote/archaea to bacteria comparison. The MTB protein database contained 106 named magnetosome genes (similarly named genes were kept separate, e.g., MamK and its paralog MamK2; ref. 64) represented by 594 sequences meeting a threshold minimum length of 100 amino acids (Dataset S3). Genes labeled as Unknown (n = 7) were excluded from consideration as uMGHs. To account for evolutionary distance, the Lokiarchaeota uMGH assessment included matches to uMGHs and similarly named MTB homologs.

The full repertoire of genes encoding uMGHs in zebrafish and Chinook salmon was identified through unidirectional BLASTp queries of fish genome contents to the magnetosome protein database, applying a threshold E < 1e3 filter to remove nonspecific matches (63). As the objective here was to identify the complete repertoire of genes with distant homology to MTB magnetite biomineralization genes, we retained both matches to named uMGHs and matches to their homologs and grouped them under a single gene identifier (i.e., MamK and MamK2 were retained and grouped as MamK). Based on the full uMGH repertoire of Chinook salmon, whether the relative frequency of DEGs characterized as uMGHs was greater than expected was tested using a one-tailed proportion test (without Yates continuity correction). The background global frequency of uMGHs was calculated by dividing the number of protein-coding uMGHs (n = 367) by the genome-wide number of protein-coding genes (n = 42,215). Only DEGs characterized as protein coding were considered in this analysis (n = 1,433 of 1,588 DEGs). Calculations were made in R package stats version 3.2.1 (61), with statistical significance set to P < 0.05.

The RNA sequencing data used for differential gene expression modeling are available through National Center for Biotechnology Information BioProject accession no. PRJNA614978. All other data are available from SI Appendix, Datasets S1S6, and public repositories as described within the text.

Chinook salmon rearing facilities were provided by the Oregon Department of Fish and Wildlife at Nestucca Hatchery, the National Oceanic and Atmospheric Administration, Northwest Fishery Science Center Newport Aquaculture Facility (Mary Arkoosh), and the Corvallis Research Group (Rob Chitwood, David Noakes, and Joseph ONeil). David Jacobson of Coastal Oregon Marine Experiment Station, Oregon State University, contributed research advice. The authors acknowledge Benot Rose for technical assistance and StephanEder for assistance with FMR measurements. M.R.B. and M.A.B. received funding from Coastal Oregon Marine Experiment Station, Project CROOS, Collaborative Research on Oregon Ocean Salmon funded by Oregon Watershed Enhancement Board and Klamath Disaster Relief Funds (National Oceanic Atmospheric Administration grant NA07NMF4540337) and other National Marine Fisheries Service funds administered through the Cooperative Institute of Marine Resources Studies. M.R.B. received support from Oregon State University scholarships (Dr. Hari S. and Dr. Renuka R. Sethi, H. Richard Carlson, Neil Armantrout, and Oregon Lottery) and Mamie Markham Research Awards administered by the Hatfield Marine Science Center. H.C. received support from the University of Strasbourg Institute for Advanced Studies. M.W. acknowledges funding from the Deutsche Forschungsgemeinschaft, grant 395940726SFB 1372 Magnetoreception and Navigation in Vertebrates. Oregon State University, Center for Genome Research and Biocomputing core facility provided RNA-seq sequencing services and advanced computing resources. Advanced computing resources were also provided by the University of HawaiiInformation Technology ServicesCyberinfrastructure, funded in part by the NSF MRI award no. 1920304. We are grateful for insightful comments by two reviewers whose recommendations substantially improved the presentation of our findings.

Author contributions: M.R.B., J.W., U.H., H.C., M.W., and M.A.B. designed research; M.R.B., J.W., U.H., H.C., and M.W. performed research; M.R.B., J.W., U.H., H.C., M.W., and M.A.B. contributed new reagents/analytic tools; M.R.B., J.W., U.H., H.C., and M.W. analyzed data; and M.R.B., J.W., U.H., H.C., M.W., and M.A.B. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2108655119/-/DCSupplemental.

Read more here:
Conservation of magnetite biomineralization genes in all domains of life and implications for magnetic sensing - pnas.org

Posted in Molecular Genetics | Comments Off on Conservation of magnetite biomineralization genes in all domains of life and implications for magnetic sensing – pnas.org

UK part of national collaboration to study long COVID-19 – ABC 36 News – WTVQ

Posted: January 20, 2022 at 2:01 am

UK College of Medicineresearchers will enroll more than 80 adult participants from Kentucky: some who have had COVID-19 and others who have not. Participants will be followed for up to four years to identify risk factors and occurrences of long COVID, medically known as post-acute sequelae of SARS-CoV-2 infection (PASC).

This study is part of the National Institutes of HealthResearching COVID to Enhance Recovery (RECOVER) Initiative. The NIH awarded the $470 million RECOVER parent award to more than 100 researchers at more than 30 institutions, creating a large-scale, national study population of diverse research volunteers, that is being coordinated by the RECOVER Clinical Science Core located at New York University Langone Health.

Together, these studies are expected to provide insights over the coming months into many important questions including the incidence and prevalence of long-term effects from SARS-CoV-2 infection, the range of symptoms, underlying causes, risk factors, outcomes, and potential strategies for treatment and prevention.

UK has partnered with West Virginia University and nine other institutions to form the IDeA States Consortium for Clinical Research (ISCORE) network, which ensures that the unique needs of the rural and medically underserved communities of Kentucky will be represented in the RECOVER study.

We get to help tell the story of the impact of COVID-19 on our state and better understand how to help our citizens recover from it, said Zach Porterfield, M.D., Ph.D., assistant professor in the UK Department of Microbiology, Immunology and Molecular Genetics, who is co-leading the study.

Of the 45 million COVID-19 cases in the U.S., it is estimated that 10-30%are long haulers. According to the Centers for Disease Control and Prevention, people commonly report prolonged symptoms including difficulty breathing or shortness of breath, tiredness or fatigue, cough, difficulty thinking or concentrating (brain-fog), chest or stomach pain, headache and cardiovascular complications including thrombosis.

This project draws multidisciplinary expertise from across the UK College of Medicine including the Departments of Microbiology, Immunology and Genetics; Molecular and Cellular Biochemistry; and Internal Medicine (Cardiology and Infectious Disease Divisions). The project is made possible by the support from UKs Center for Clinical and Translational Science (CCTS) and the Virus Induced Thrombosis Alliance (VITAL). The VITAL team, funded through the College of Medicines Research Alliance Initiative, investigates why viral infections cause an increased risk of cardiovascular disease. VITAL research early in the COVID-19 pandemic suggested the risk of thrombosis could persist after the SARS-CoV-2 infection clears.

This important study is a wonderful example of how teams of clinicians, basic scientists, and support staff at UK work together to address health care problems in the Commonwealth and the nation, said the studys co-principal investigatorSidney Whiteheart, Ph.D., professor in the Department of Molecular and Cellular Biochemistry.

For those interested in learning more about this study or participating, please emailKITE@uky.edu.

Read more here:
UK part of national collaboration to study long COVID-19 - ABC 36 News - WTVQ

Posted in Molecular Genetics | Comments Off on UK part of national collaboration to study long COVID-19 – ABC 36 News – WTVQ

COVID-19 may cause fetal inflammation even in absence of placental infection, researchers report Sc… – newsconcerns

Posted: January 20, 2022 at 2:01 am

Researchers at the Wayne State University School of Medicine and the National Institutes of Healths Perinatology Research Branch in Detroit have found that SARS-CoV-2, the virus that causes COVID-19, may cause fetal inflammation even in the absence of placental infection.

Pregnant women have a higher risk of severe illness if infected with COVID-19. Infection increases the risk of preterm birth, stillbirth and preeclampsia.

Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2, published today in the journal Nature Communications, reports that COVID-19 infection during pregnancy may cause inflammatory immune responses in the fetus, even if the virus does not infect the placenta.

The study, conducted by Nardhy Gomez-Lopez, Ph.D., associate professor of the WSU Department of Obstetrics and Gynecology, and section head of the Maternal-Fetal Immunobiology Unit, and Roberto Romero, M.D., D.Med.Sci., chief of the NIHs Perinatology Research Branch, based at the Wayne State University School of Medicine, and professor of Molecular Obstetrics and Genetics at the WSU School of Medicine, details changes in antibodies, immune cell types and inflammatory markers in maternal blood, umbilical cord blood and placental tissues.

We found that in pregnant mothers who contract the virus, SARS-CoV-2 induces a fetal immune response even in the absence of placental infection or symptoms in the newborn. The potential long-term effects of this inflammatory process on infants requires further study, Dr. Gomez-Lopez said.

The researchers evaluated 23 pregnant women. Twelve tested positive for SARS-CoV-2, and of those, eight were asymptomatic, one had mild symptoms and three had severe COVID-19. After delivery, the researchers compared immune responses between mothers and their newborns by comparing maternal blood and umbilical cord blood. Inflammatory immune responses triggered by the virus were observed in women, their newborns and placental tissues regardless of whether the mothers displayed symptoms.

The study team described the following observations:

This study provides insight into the maternal-fetal immune responses triggered by SARSCoV-2 and emphasizes the rarity of placental infection, Dr. Romero said. Most pregnant women with SARS-CoV-2 infection are asymptomatic or only experience mild symptoms. Regardless, in the first six months of the COVID-19 pandemic, it was documented that infected pregnant women are at an increased risk for hospitalization, mechanical ventilation, intensive care unit admission and preterm birth, but rates of maternal mortality were reported to be similar between pregnant and non-pregnant women. More recently, it has been clearly shown that pregnant women are at high risk for severe disease and death, as well as preterm birth. Investigating host immune responses in pregnant women who are infected, even if they are asymptomatic, is timely.

These latest findings will help researchers better understand COVID-19 during pregnancy. The authors noted that the potential long-term effects of this inflammatory process on infants requires further study.

This research was supported by the Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS) under Contract No. HHSN275201300006C. This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health.

See original here:
COVID-19 may cause fetal inflammation even in absence of placental infection, researchers report Sc... - newsconcerns

Posted in Molecular Genetics | Comments Off on COVID-19 may cause fetal inflammation even in absence of placental infection, researchers report Sc… – newsconcerns

The Doomsday Clock measures more than nuclear risk and it’s about to be reset again – Stuff.co.nz

Posted: January 20, 2022 at 2:01 am

Jack Heinemann is a Professor of Molecular Biology and Genetics at the University of Canterbury.

OPINION: In less than 24 hours the Bulletin of the Atomic Scientists will update the Doomsday Clock. Its currently at 100 seconds from midnight the metaphorical time when the human race could destroy the world with technologies of its own making.

The hands have never before been this close to midnight. There is scant hope of it winding back on what will be its 75th anniversary.

The clock was originally devised as a way to draw attention to nuclear conflagration. But the scientists who founded the Bulletin in 1945 were less focused on the initial use of the bomb than on the irrationality of stockpiling weapons for the sake of nuclear hegemony.

READ MORE:* Burnout risk for climate change activists suffering 'hopelessness' and 'despair'* Are earthships the answer to our climate change and housing problems?* How climate change impacts what fruit and vegetables we can grow in our gardens

They realised more bombs did not increase the chances of winning a war or make anyone safe when just one bomb would be enough to destroy New York City.

While nuclear annihilation remains the most probable and acute existential threat to humanity, it is now only one of the potential catastrophes the Doomsday Clock measures. As the Bulletin puts it: The Clock has become a universally recognised indicator of the worlds vulnerability to catastrophe from nuclear weapons, climate change, and disruptive technologies in other domains.

At a personal level, I feel some sense of academic kinship with the clockmakers. Mentors of mine, notably Aaron Novick, and others who profoundly influenced how I see my own scientific discipline and approach to science, were among those who formed and joined the early Bulletin.

In 2022, their warning extends beyond weapons of mass destruction to include other technologies that concentrate potentially existential hazards including climate change and its root causes in over-consumption and extreme affluence.

Many of these threats are well known already. For example, commercial chemical use is all pervasive, as is the toxic waste it creates. There are tens of thousands of large scale waste sites in the US alone, with 1700 hazardous superfund sites prioritised for clean-up.

As Hurricane Harvey showed when it hit the Houston area in 2017, these sites are extremely vulnerable. An estimated two million kilograms of airborne contaminants above regulatory limits were released, 14 toxic waste sites were flooded or damaged, and dioxins were found in a major river at levels over 200 times higher than recommended maximum concentrations.

That was just one major metropolitan area. With increasing storm severity due to climate change, the risks to toxic waste sites grow.

At the same time, the Bulletin has increasingly turned its attention to the rise of artificial intelligence, autonomous weaponry, and mechanical and biological robotics.

The movie clichs of cyborgs and killer robots tend to disguise the true risks. For example, gene drives are an early example of biological robotics already in development. Genome editing tools are used to create gene drive systems that spread through normal pathways of reproduction but are designed to destroy other genes or offspring of a particular sex.

AP

Scientists Robert Rosner (right) and Lawrence Krauss (left), unveil the Doomsday Clock during a news conference at the National Press Club in Washington in 2018. The clock is currently set at 100 seconds to midnight.

As well as being an existential threat in its own right, climate change is connected to the risks posed by these other technologies.

Both genetically engineered viruses and gene drives, for example, are being developed to stop the spread of infectious diseases carried by mosquitoes, whose habitats spread on a warming planet.

Once released, however, such biological robots may evolve capabilities beyond our ability to control them. Even a few misadventures that reduce biodiversity could provoke social collapse and conflict.

Similarly, its possible to imagine the effects of climate change causing concentrated chemical waste to escape confinement. Meanwhile, highly dispersed toxic chemicals can be concentrated by storms, picked up by floodwaters and distributed into rivers and estuaries.

The result could be the despoiling of agricultural land and freshwater sources, displacing populations and creating chemical refugees.

Given that the Doomsday Clock has been ticking for 75 years, with myriad other environmental warnings from scientists in that time, what of humanitys ability to imagine and strive for a different future?

Part of the problem lies in the role of science itself. While it helps us understand the risks of technological progress, it also drives that process in the first place. And scientists are people, too part of the same cultural and political processes that influence everyone.

J Robert Oppenheimer the father of the atomic bomb described this vulnerability of scientists to manipulation, and to their own naivete, ambition and greed, in 1947: In some sort of crude sense which no vulgarity, no humour, no overstatement can quite extinguish, the physicists have known sin; and this is a knowledge which they cannot lose.

If the bomb was how physicists came to know sin, then perhaps those other existential threats that are the product of our addiction to technology and consumption are how others come to know it, too.

Ultimately, the interrelated nature of these threats is what the Doomsday Clock exists to remind us of.

This article was originally published on The Conversation. Read the original article.

Continue reading here:
The Doomsday Clock measures more than nuclear risk and it's about to be reset again - Stuff.co.nz

Posted in Molecular Genetics | Comments Off on The Doomsday Clock measures more than nuclear risk and it’s about to be reset again – Stuff.co.nz

Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer – StreetInsider.com

Posted: January 20, 2022 at 2:00 am

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

SAN FRANCISCO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Fountain Therapeutics (Fountain), a biopharmaceutical company leveraging a unique artificial intelligence platform driven by expertise in aging biology to build a pipeline of disease-modifying therapeutics for chronic degenerative diseases, today announced the appointment of Anupama Hoey as chief business officer (CBO) effective January 17th, 2022.

We are pleased to welcome Ms. Hoey to our executive management team to support our next phase of growth, said William Greene, M.D., chief executive officer of Fountain Therapeutics. Her considerable expertise in business development, corporate strategy, drug discovery, and research and development will be very valuable as we continue to generate insights from our artificial intelligence platform and grow our pipeline of therapeutics aimed at extending the healthspan of people living with chronic degenerative diseases.

Ms. Hoey, added, I am delighted to join Fountain at this exciting time as the company continues to translate the potential of its screening and discovery platform into relevant biomarkers of disease and potential therapeutic leads. I am impressed by its innovative artificial intelligence and machine learning technologies which, combined with the teams deep expertise in aging research, is identifying novel biology and insights for risk factors of disease. Importantly, we are also using this platform to discover compounds that work to restore resilience of cells and tissues to treat chronic diseases of aging.

Ms. Hoey has over 20 years of financing and business development expertise with private life sciences companies leading corporate development, strategic collaborations, and licensing and spin-out ventures with large economic value to companies. Prior to joining Fountain, Ms. Hoey was CBO at Sensei Biotherapeutics, where she played a key role in Senseis successful $152M IPO. Prior to Sensei, Ms. Hoey served as the CBO of Second Genome Inc., where she executed a multi-program drug discovery and biomarker deal with Gilead Sciences worth up to $1.5B. Previously, Ms. Hoey held positions of increasing responsibility at multiple biotech companies including Invenra, Inc., Arcus Biosciences and Sutro Biopharma, where she executed multiple strategic transactions with major pharmaceutical companies, including Celgene, EMD Serono and Exelixis. Ms. Hoey holds a bachelors degree in molecular genetics from The Ohio State University,a masters degree in molecular biology from Case Western Reserve University and a M.B.A. from the University of San Francisco.

About Fountain TherapeuticsFountain Therapeutics is a biopharmaceutical company building a pipeline of disease-modifying therapeutics for chronic degenerative diseases. The companys cell-based AI-driven technology platform leverages recent developments in machine learning and computer vision, along with deep insight into the biology of aging, to enable precise mapping of cellular biologic age, a marker of resilience and health. The platform enables extraction of cellular features that provide extensive insight into the aging process of cells, which may lead to identification of novel targets and disease biomarkers. Fueled by the expertise of leaders in aging research and computation, Fountain has turned these insights and technology into an unbiased drug discovery and development engine that introduces a new avenue for the discovery and advancement of therapies for chronic degenerative diseases.

For more information, please visit fountaintx.com and follow the company on Twitter: FountainTx.

Media Contact:Patrick Bursey LifeSci Communications(646) 970-4688 pbursey@lifescicomms.com

Go here to read the rest:
Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer - StreetInsider.com

Posted in Molecular Genetics | Comments Off on Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer – StreetInsider.com

Page 539«..1020..538539540541..550560..»